Browsing: Mortality Risk
Longevity and Mortality Investor’s coverage of bulk purchase annuity transactions. We are a leading source globally for mortality risk analysis, commentary and insights.
The past four decades have brought revolutionary improvements in cancer care, transforming many forms of cancer from fatal diagnoses into chronic, manageable conditions.
The subject of whether life insurance-linked securities (life ILS) structures should be rated or not is a conversation almost as old as the market itself.
Litigation risk in the life settlement market takes multiple forms, from cost of insurance increases to estate challenges, from credit risk to stranger-owned life insurance cases. Liam Bodemeaid, Actuarial Consultant at Actuarial Risk Management, introduces a new framework to price litigation risk with a little bit more logic, data, and structure in a guest article.
The longevity economy is multi-faceted, with a range of investment opportunities available that can impact longevity in different ways. Greg Winterton spoke to Sergey Jakimov, Founding Partner of venture capital firm LongeVC, to get his views on both the space overall, and how LongeVC sees it, and therefore, approaches it in our latest Q&A.
Longevity and Mortality Investor (LMI) is the new name for Life Risk News. Greg Winterton caught up with Chris Wells, Managing Editor at LMI, to discuss the reasons behind the rebrand, his thoughts on how the longevity and mortality markets have evolved in recent years, and plans for the future.
Athene will reinsure an in-force block of US dollar denominated whole life insurance policies and will enter into an agreement with reinsurer Swiss Re to retrocede all mortality risk associated with the block.
HSCM Bermuda Closes Secondaries Fund to Acquire Life Insurance-Linked Securities Portfolio: HS Sawmill LP closes with $110m of capital commitments.
The number of policies sold rose 7% in the second quarter, which is the highest growth rate recorded in LIMRA’s quarterly survey since 1983.
A recent article in The Lancet Public Health suggests that walking 7,000 steps is associated with reductions in the risk of several serious health outcomes.
Two areas of research are providing the gerontology community with the most promise: dysregulated nutrient sensing and cell senescence.